Phyton has extended its business relationship with Bristol-Myers Squibb, by signing a long-term, multimillion-dollar deal for supply of the plant-derived taxane drug, paclitaxel.
Phyton is a biotechnology company focused on the production of high-value chemical compounds through its proprietary plant cell fermentation technology.
